Tenon Medical, Inc.
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
TNON$1.74-0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Convertible Preferred Stock and Stockholders’ Equity
Condensed Statements of Convertible Preferred Stock and Stockholders’ Equity (Unaudited)
(In thousands, except share data)
Three months ended March 31, 2025 and 2024:
| Series A Convertible Preferred Stock · Series B Convertible Preferred Stock · Common Stock · Additional Paid-In · Accumulated · Accumulated Other Comprehensive | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | Loss | Total | |
| Balance at December 31, 2024 | 256,968 | $3,300 | 86,454 | $452 | 3,138,804 | $3 | $70,962 | $(68,746) | $— | $5,971 |
| Stock-based compensation expense | — | — | — | — | — | — | 872 | — | — | 872 |
| Issuance of common stock, pre-funded warrants and warrants under inducement agreement, net of issuance costs | — | — | — | — | 2,445,700 | 3 | 2,732 | — | — | 2,735 |
| Issuance of common stock, prefunded warrants, and warrants, net of issuance costs | — | — | — | — | 2,005,000 | 2 | 3,522 | — | — | 3,524 |
| Release of restricted stock units | — | — | — | — | 461 | — | — | — | — | — |
| Deferred deal costs | — | — | — | — | — | — | (110) | — | — | (110) |
| Net loss | — | — | — | — | — | — | — | (3,616) | (3,616) | |
| Balance at March 31, 2025 | 256,968 | $3,300 | 86,454 | $452 | 7,589,965 | $8 | $77,978 | $(72,362) | $— | $9,376 |
| Balance at December 31, 2023 | — | — | — | — | 325,039 | — | 55,897 | (55,073) | (46) | 778 |
| Stock-based compensation expense | — | — | — | — | — | — | 1,018 | 1,018 | ||
| Issuance of common stock, net of issuance costs | — | — | — | — | 140,430 | — | 1,804 | 1,804 | ||
| Issuance of Series A preferred stock and warrants, net of issuance costs | 256,968 | 3,300 | — | — | — | — | 254 | — | — | 3,554 |
| Release of restricted stock units | — | — | — | — | 403 | — | — | — | — | — |
| Other comprehensive income | — | — | — | — | — | — | — | — | 46 | 46 |
| Net loss | — | — | — | — | — | — | — | (3,576) | (3,576) | |
| Balance at March 31, 2024 | 256,968 | $3,300 | — | $— | 465,872 | $— | $58,973 | $(58,649) | $— | $3,624 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.